Clinical Trials Logo

Epilepsy clinical trials

View clinical trials related to Epilepsy.

Filter by:

NCT ID: NCT05042726 Completed - Clinical trials for Drug Refractory Epilepsy

cTBS Targeting Cerebellum for Drug-refractory Epilepsy

Start date: August 2, 2021
Phase: N/A
Study type: Interventional

This study aims to observe the effect and safety of cerebellar continuous θ burst stimulation (cTBS) for drug-refractory epilepsy(DRE), in order to provide a new treatment for DRE and improve the quality of life of those patients. A total of 44 patients with DRE will have cTBS via accurate navigation to bilateral cerebellar dentate nuclei. Patients will be randomised into 2 groups in a crossover trial design to have 2 week periods of cTBS separated by 8 week washout periods, following which the patient will cross over to have the opposite condition for a further 2 week. Frequency and symptoms of seizures, scalp EEG, clinical scores, and QOLIE-31 were assessed at baseline and after 1 and 2 month of treatment.

NCT ID: NCT05031208 Completed - Refractory Epilepsy Clinical Trials

Acute and Long Term Effects of VNS on Memory in Patients With Refractory Epilepsy

Start date: November 22, 2018
Phase: N/A
Study type: Interventional

Refractory epilepsy patients implanted with a vagus nerve stimulator perform a memory test at baseline in three conditions: invasive vagus nerve stimulation (VNS), transcutaneous vagus nerve stimulation (taVNS) and sham stimulation. After 6 weeks of VNS treatment, the memory test is repeated in two condition: invasive vagus nerve stimulation (VNS) and sham stimulation. The endpoint of this experiment is assessing the effect of VNS and taVNS on memory performance.

NCT ID: NCT05011773 Completed - Parkinson Disease Clinical Trials

Manipulating and Optimising Brain Rhythms for Enhancement of Sleep

MORPHEUS
Start date: August 3, 2021
Phase: N/A
Study type: Interventional

Treatment of sleep disturbances is mainly attempted through drug administration. However, certain drugs are associated with unwanted side effects or residual effects upon awakening (e.g. sleepiness, ataxia) which can increase the risks of falls and fractures. In addition, there can be systemic consequences of long-term use. An alternative method of manipulating sleep is by stimulating the brain to influence the electroencephalogram (EEG). To date, there have been mixed results from stimulating superficial areas of the brain and, as far as we know, there has been no systematic attempt to influence deep brain activity. Many patients suffering from movement disorders, such as Parkinson's Disease (PD) and Multiple Systems Atrophy (MSA), also have disrupted sleep. Currently, at stages where drug treatment no longer offers adequate control of their motor symptoms, these patients are implanted with a deep brain stimulation system. This involves depth electrodes which deliver constant pulse stimulation to the targeted area. A similar system is used in patients with severe epilepsy, as well as some patients with chronic pain. The aim of this feasibility study is to investigate whether we can improve sleep quality in patients with deep brain stimulators by delivering targeted stimulation patterns during specific stages of sleep. We will only use stimulation frequencies that have been proven to be safe for patients and frequently used for clinical treatment of their disorder. We will examine the structure and quality of sleep as well as how alert patients are when they wake up, while also monitoring physiological markers such as heart rate and blood pressure. Upon awakening, we will ask the patients to provide their subjective opinion of their sleep and complete some simple tests to see how alert they are compared to baseline condition which would be either stimulation at the standard clinical setting or no stimulation. We hope that our study will open new ways of optimising sleep without the use of drugs, in patients who are implanted with depth electrodes. We also believe that our findings will broaden the understanding of how the activity of deep brain areas influences sleep and alertness.

NCT ID: NCT05008354 Completed - Epilepsy Clinical Trials

Effect of Pyridoxine on Behavioral Adverse Events of Levetiracetam

EPYLEB
Start date: October 1, 2020
Phase: Phase 4
Study type: Interventional

This study is a two-arm parallel group randomized double-blind placebo-controlled trial with the aim of Investigating pyridoxine effect on behavioral side effects of levetiracetam in adult patients with epilepsy.

NCT ID: NCT04967326 Completed - Epilepsy Clinical Trials

Role of Clinical Pharmacists in Epilepsy Management

Start date: January 1, 2016
Phase: Phase 4
Study type: Interventional

Clinical pharmacists have an important role in inter-professional healthcare collaboration for epilepsy management. However, the pharmacy practices of managing epilepsy are still limited in Vietnam, deterring pharmacists from routine adjustments of antiepileptic drugs, which could decrease the patients' quality of life. This study aimed to assess the effectiveness of pharmacist interventions in epilepsy treatment at a Vietnamese general hospital.

NCT ID: NCT04965571 Completed - Wilson Disease Clinical Trials

Clinical Features and Outcome of Wilson's Disease With Generalized Epilepsy in Chinese Patients

Start date: September 1, 2010
Phase:
Study type: Observational

Generalized epilepsy is rarely reported in patients with Wilson disease (WD) and lacks experience in clinical practice. We aim to provide better experience for the diagnosis and treatment for WD patients with epilepsy in the future.

NCT ID: NCT04954729 Completed - Epilepsy, Rolandic Clinical Trials

Association of Processing Speed Dysfunction and Brain Functional Abnormality in ECTS

Start date: June 1, 2019
Phase:
Study type: Observational

Epilepsy with centrotemporal spikes (ECTS) is the most common epilepsy syndrome in children. Language impairment has been widely investigated in patients with ECTS, but little is known about the cognitive dysfunction of processing speed and its neuroimaging mechanism.

NCT ID: NCT04924153 Completed - Clinical trials for KCNT1-Related Epilepsy

A Natural History Study of Participants With Potassium Sodium-Activated Channel Subfamily T Member 1 (KCNT1)-Related Epilepsy

K1Te
Start date: August 17, 2021
Phase:
Study type: Observational

The primary objective of the study is to characterize seizures in participants with KCNT1-related epilepsy. The secondary objectives are to characterize head growth, symptom severity, neurocognitive and social functions, adaptive behavior, sleep, quality of life, caregiver burden, and mood in participants with KCNT1-related epilepsy.

NCT ID: NCT04888637 Completed - Epilepsy Clinical Trials

Pediatric Language and Memory Mapping in Refractory Epilepsy Using Magnetoencephalography

Start date: July 14, 2021
Phase:
Study type: Observational

This is a pilot research study where language and working memory tasks will be used to study brain activities from children with epilepsy. Specifically for language assessment, a well-known MEG language protocol will be used and novel signal processing techniques will be applied. A widely utilized paradigm will be used to study memory function and adapt signal-processing techniques from previous literature for the processing and analysis of MEG signals collected during memory task. No treatment/intervention will be performed or evaluated in this pilot research study.

NCT ID: NCT04857307 Completed - Epilepsy Clinical Trials

A Study to Assess the Pharmacokinetics (PK) and Safety of Staccato Alprazolam in Adolescent Study Participants With Epilepsy

Start date: April 28, 2021
Phase: Phase 1
Study type: Interventional

The purpose of the study is to assess the pharmacokinetics (PK), tolerability, and safety of Staccato alprazolam in adolescent study participants with epilepsy following single-dose administration.